Logo for Toleranzia

Toleranzia Investor Relations Material

Latest events

Logo for Toleranzia

Q2 2024

23 Aug, 2024
Logo for Toleranzia

Q1 2024

20 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Toleranzia

Access all reports
Toleranzia AB is a biotechnology company specializing in the development of protein-based drugs for the treatment of autoimmune diseases. The company leverages its proprietary platform to create therapeutic proteins aimed at inducing immune tolerance in patients, addressing the underlying causes of autoimmune conditions rather than merely alleviating symptoms. Toleranzia focuses on diseases with significant unmet medical needs, striving to provide innovative treatments that can improve patients' quality of life. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Stockholm Stock Exchange.